DW Documentary – Yemen: the world looks away | DW Documentary
Yemen has become a humanitarian catastrophe. The country has been devastated by a civil war and Yemen is facing the worst famine in decades. The proxy war between Saudi Arabia and Iran, the bitter conflict between Sunnis and Shias, has devastated Yemen and laid the foundations for radicalization and terrorism. Our reporters have been there – a land usually closed off to foreign journalists. Ten thousand fatalities, 300,000 internal displacements and as many as two million refugees – the United Nations says the country is going through its worst humanitarian crisis since the Second World War. And yet, the outside world seems to hear little or nothing about this Middle Eastern conflict. The warring parties have all but sealed the country off. ‘Yemen: The World Looks Away’ offers unprecedented insights into the plight of a country where bombs, battles, famine and disease have ravaged the population. Our reporters traveled from Aden in the south of the country to Sanaa in the north, crossing the frontline that divides them at Tais. They were accompanied by Peter Maurer, president of the International Committee of the Red Cross, one of the few people who have actually traveled widely within the country. ‘Yemen: The World Looks Away’ portrays a country destroyed by civil war, caught up in the struggles between regional powers and all but ignored by the international community. _______ Exciting, powerful and informative – DW Documentary is always close to current affairs and international events. Our eclectic mix of award-winning films and reports take you straight to the heart of the story. Dive into different cultures, journey across distant lands, and discover the inner workings of modern-day life. Subscribe and explore the world around you – every day, one DW Documentary at a time. Subscribe to DW Documentary: https://www.youtube.com/dwdocumentary… For more information visit: http://www.dw.com/en/tv/docfilm/s-3610 Instagram https://www.instagram.com/dwdocumentary/ Facebook: https://www.facebook.com/dw.stories DW netiquette policy: http://www.dw.com/en/dws-netiquette-p…
Routine administration of the smallpox vaccine ended in the United States in 1972. With the reinitiation of the US smallpox vaccination program in 2002, the risk of transmission of vaccinia virus from a recently vaccinated person to a susceptible host is a concern. Secondary transmission is biologically plausible because of evidence of viral persistence in vaccinees. Vaccinia virus has been cultured from the oropharynx of vaccine recipients with a normal course following vaccination.1 In the 1960s and 1970s, it was isolated from the blood and urine of a limited number of vaccine recipients who had complications following vaccination.2 More sensitive molecular techniques are now available for detecting viruses in clinical specimens. We describe findings using real-time polymerase chain reaction (PCR) to detect vaccinia DNA in smallpox vaccine recipients
US National Library of Medicine
National Institutes of Health – 2014
Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W.
Author information
Chinese Center for Disease Control and Prevention.
Abstract
China has long experience using live attenuated and inactivated vaccines against hepatitis A virus (HAV) infection. We summarize this experience and provide recent data on adverse events after immunization (AEFIs) with hepatitis A vaccines in China. We reviewed the published literature (in Chinese and English) and the published Chinese regulatory documents on hepatitis A vaccine development, production, and postmarketing surveillance of AEFI. We described the safety, immunogenicity, and efficacy of hepatitis A vaccines and horizontal transmission of live HAV vaccine in China. In clinical trials, live HAV vaccine was associated with fever (0.4%-5% of vaccinees), rash (0%-1.1%), and elevated alanine aminotransferase (0.015%). Inactivated HAV vaccine was associated with fever (1%-8%), but no serious AEFIs were reported. Live HAV vaccine had seroconversion rates of 83% to 91%, while inactivated HAV vaccine had seroconversion rates of 95% to 100%. Community trials showed efficacy rates of 90% to 95% for live HAV and 95% to 100% for inactivated HAV vaccine. Postmarketing surveillance showed that HAV vaccination resulted in an AEFI incidence rate of 34 per million vaccinees, which accounted for 0.7% of adverse events reported to the China AEFI monitoring system. There was no difference in AEFI rates between live and inactivated HAV vaccines. Live and inactivated HAV vaccines manufactured in China were immunogenic, effective, and safe. Live HAV vaccine had substantial horizontal transmission due to vaccine virus shedding; thus, further monitoring of the safety of virus shedding is warranted.
US National Library of Medicine
National Institutes of Health – Nov 2016
Jeong S – 1, Than VT – 1, Lim I – 2, Kim W – 3
Author information
1 Department of Microbiology, Chung-Ang University College of Medicine, Seoul, South Korea.
2 Department of Pediatrics, Chung-Ang University College of Medicine, Seoul, South Korea.
3 Department of Microbiology, Chung-Ang University College of Medicine, Seoul, South Korea. Electronic address: kimwy@cau.ac.kr.
Abstract
RotaTeq® is a live attenuated human-bovine reassortant vaccine against rotaviruses that is used worldwide. However, shedding of the virus used in RotaTeq® has been detected in the feces of children following vaccination by the oral route, possibly affecting community immunity. Therefore, a simple and efficient method to discriminate between virulent and RotaTeq® vaccine strains is required. In this study, a novel one-step multiplex reverse-transcription polymerase chain reaction (RT-PCR) assay targeting the NSP3 gene was developed to detect RotaTeq® vaccine strains in fecal samples. RotaTeq® vaccine viruses were successfully distinguished from known wild-type rotavirus genotypes. In addition, the developed assay was able to detect rotaviruses in clinical stool samples obtained from South Korea during the 2011-2013 rotavirus seasons. Of the 1106 stool specimens from children with acute gastroenteritis that were screened, 286 rotaviruses were genotyped. RotaTeq® vaccine strains were identified in 39 samples (13.6%). The novel RT-PCR assay that was developed could be used to detect and discriminate between RotaTeq® vaccine strains that are shed in fecal matter, and to estimate the quantification of virus that has been shed after vaccination.
VAXXED TV – Something is Wrong
I Really Trusted Her
100% Proof! Human DNA in Vaccines
More M.D.s Come Forward
Adam’s Letter Board
We signed his life away
What kills 7,300 babies in the United States each year?
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
1 Who hath believed our report? and to whom is the arm of the Lord revealed?
2 For he shall grow up before him as a tender plant,and as a root out of a dry ground:he hath no form nor comeliness;and when we shall see him,there is no beauty that we should desire him.
3 He is despised and rejected of men;a man of sorrows, and acquainted with grief:and we hid as it were our faces from him;he was despised, and we esteemed him not.
4 Surely he hath borne our griefs,and carried our sorrows:yet we did esteem him stricken,smitten of God, and afflicted.
5 But he was wounded for our transgressions,he was bruised for our iniquities:the chastisement of our peace was upon him;and with his stripes we are healed.
6 All we like sheep have gone astray;we have turned every one to his own way;and the Lord hath laid on him the iniquity of us all.
7 He was oppressed, and he was afflicted,yet he opened not his mouth:he is brought as a lamb to the slaughter,and as a sheep before her shearers is dumb,so he openeth not his mouth.
8 He was taken from prison and from judgment:and who shall declare his generation? for he was cut off out of the land of the living:for the transgression of my people was he stricken.
9 And he made his grave with the wicked,and with the rich in his death;because he had done no violence,neither was any deceit in his mouth.
10 Yet it pleased the Lord to bruise him;he hath put him to grief:when thou shalt make his soul an offering for sin,he shall see his seed, he shall prolong his days,and the pleasure of the Lord shall prosper in his hand.
11 He shall see of the travail of his soul, and shall be satisfied:by his knowledge shall my righteous servant justify many;for he shall bear their iniquities.
12 Therefore will I divide him a portion with the great,and he shall divide the spoil with the strong;because he hath poured out his soul unto death:and he was numbered with the transgressors;and he bare the sin of many,and made intercession for the transgressors.
Abstract
In this study, the Vaccine Adverse Event Reporting System (VAERS) database, 1990-2010, was investigated; cases that specified either hospitalization or death were identified among 38,801 reports of infants. Based on the types of vaccines reported, the actual number of vaccine doses administered, from 1 to 8, was summed for each case. Linear regression analysis of hospitalization rates as a function of (a) the number of reported vaccine doses and (b) patient age yielded a linear relationship with r(2) = 0.91 and r(2) = 0.95, respectively. The hospitalization rate increased linearly from 11.0% (107 of 969) for 2 doses to 23.5% (661 of 2817) for 8 doses and decreased linearly from 20.1% (154 of 765) for children aged <0.1 year to 10.7% (86 of 801) for children aged 0.9 year. The rate ratio (RR) of the mortality rate for 5-8 vaccine doses to 1-4 vaccine doses is 1.5 (95% confidence interval (CI), 1.4-1.7), indicating a statistically significant increase from 3.6% (95% CI, 3.2-3.9%) deaths associated with 1-4 vaccine doses to 5.5% (95% CI, 5.2-5.7%) associated with 5-8 vaccine doses. The male-to-female mortality RR was 1.4 (95% CI, 1.3-1.5). Our findings show a positive correlation between the number of vaccine doses administered and the percentage of hospitalizations and deaths. Since vaccines are given to millions of infants annually, it is imperative that health authorities have scientific data from synergistic toxicity studies on all combinations of vaccines that infants might receive. Finding ways to increase vaccine safety should be the highest priority.
Vaccines Developed Using Human Cell Strains
The first licensed vaccine made with the use of a human cell strain was the adenovirus vaccine used by the military in the late 1960s. Later, other vaccines were developed in human cell strains, most notably the rubella vaccine developed by Stanley Plotkin, MD, at the Wistar Institute in Philadelphia.
In 1941, Australian ophthalmologist Norman Gregg first realized that congenital cataracts in babies were the result of their mothers being infected with rubella during pregnancy. Along with cataracts, it was eventually determined that congenital rubella syndrome (CRS) could also cause deafness, heart disease, encephalitis, mental retardation, and pneumonia, among many other conditions. At the height of a rubella epidemic that began in Europe and spread to the United States in the mid-1960s, Plotkin calculated that 1% of all births at Philadelphia General Hospital were affected by congenital rubella syndrome. In some cases, women who were infected with rubella while pregnant terminated their pregnancies due to the serious risks from CRS.
Following one such abortion, the fetus was sent to Plotkin at the laboratory he had devoted to rubella research. Testing the kidney of the fetus, Plotkin found and isolated the rubella virus. Separately, Leonard Hayflick (also working at the Wistar Institute at that time) developed a cell strain called WI-38 using lung cells from an aborted fetus. Hayflick found that many viruses, including rubella, grew well in the WI-38, and he showed that it proved to be free of contaminants and safe to use for human vaccines.
Plotkin grew the rubella virus he had isolated in WI-38 cells kept at 86°F (30°C), so that it eventually grew very poorly at normal body temperature. (He chose the low temperature approach following previous experiences with attenuating poliovirus.) After the virus had been grown through the cells 25 times at the lower temperature, it was no longer able to replicate enough to cause illness in a living person, but was still able to provoke a protective immune response. The rubella vaccine developed with WI-38 is still used throughout much of the world today as part of the combined MMR (measles, mumps, and rubella) vaccine.
Adenovirus DTaP-IPV/Hib (Pentacel) Hep A (Havrix) Hep B (Engerix-B) Hep A/Hep B (Twinrix) MMR (MMR-II) MMRV (ProQuad) Rabies (Imovax) Varicella (Varivax) Zoster (Shingles – Zostavax)
Excipients Included in U.S. Vaccines, by Vaccine
In addition to weakened or killed disease antigens (viruses or bacteria), vaccines contain very small amounts of other
ingredients – excipients or media.
Some excipients are added to a vaccine for a specific purpose. These include:
Preservatives, to prevent contamination. For example, thimerosal.
Adjuvants, to help stimulate a stronger immune response. For example, aluminum salts.
Stabilizers, to keep the vaccine potent during transportation and storage. For example, sugars or gelatin.
Others are residual trace amounts of materials that were used during the manufacturing process and removed. These include:
Cell culture materials, used to grow the vaccine antigens. For example, egg protein, various culture media.
Inactivating ingredients, used to kill viruses or inactivate toxins. For example, formaldehyde.
Antibiotics, used to prevent contamination by bacteria. For example, neomycin.
The following table lists all components, other than antigens, shown in the manufacturers’ package insert (PI) for each vaccine.
Each of these PIs, which can be found on the FDA’s website (see below) contains a description of that vaccine’s manufacturing
process, including the amount and purpose of each substance. In most PIs, this information is found in Section 11: “Description.”
All information was extracted from manufacturers’ package inserts, current as of January 6, 2017.
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
the news network 